Isatuximab

8:13
Treatment strategies for high-risk MM
Jesus San Miguel
7:04
Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T
Saad Usmani
6:33
MRD as a tool to discontinue therapy in MM?
Luciano Costa
10:19
Key game-changers in multiple myeloma
Kenneth Anderson
13:14
Amyloidosis: diagnosis and stem cell transplantation
Morie Gertz et al.
12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al.
1:11
Attacking plasma cell dyscrasia in AL amyloidosis
Vaishali Sanchorawala
10:42
Highlights from IMW 2019 Part I
Francesca Gay et al.
1:55
Katja Weisel: GMMG-CONCEPT
Katja Weisel
5:22
Updates on German clinical trials in multiple myeloma
Marc Raab
7:37
Prevention and management of adverse events in relapsed myeloma
Michel Delforge
3:30
Isatuximab: an important new option in R/R MM
Paul Richardson
1:24
Multiple myeloma treatment strategies: what does the future hold?
Enrique Ocio
2:24
Drug trial updates in multiple myeloma and SMM
Enrique Ocio
5:22
ICARIA study: Isatuximab and pom/dex for multiple myeloma
Paul Richardson
3:23
Upcoming updates in multiple myeloma
Thierry Facon
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals